Novartis execs highlight progress of slimmer pipeline after Sandoz spinoff

No­var­tis ex­ec­u­tives on Tues­day crys­tal­lized their on­go­ing R&D strat­e­gy shift in the wake of the San­doz spin­off, with CEO Vas Narasimhan and oth­ers out­lin­ing how the com­pa­ny aims to be more ef­fi­cient and its de­ci­sions stream­lined.

Gone are the days of “Wild Card” drugs, re­placed by a slimmed-down pipeline with much more “align­ment” across de­part­ments about which dis­eases to tack­le. It marks a shift from the past, the CEO said, about mak­ing sure No­var­tis is “very, very clear” on the dis­eases it wants to treat and drugs it wants to pur­sue.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.